An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder By Guilherme GuainJune 30, 2022
St. John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study By Guilherme GuainJune 30, 2022
Treatment of somatoform disorders with St. John’s wort: a randomized, double-blind and placebo-controlled trial By Guilherme GuainJune 30, 2022
St John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial By Guilherme GuainJune 30, 2022
St John’s wort versus placebo in obsessive-compulsive disorder: results from a double-blind study By Guilherme GuainJune 30, 2022
Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. By Guilherme GuainJune 30, 2022
S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine By Guilherme GuainJune 30, 2022
Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. By Guilherme GuainJune 30, 2022
Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant By Guilherme GuainJune 30, 2022
